ImmuPharma plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMMPF research report →
About the company
ImmuPharma plc, established in London, United Kingdom, in 1999, is a biopharmaceutical company dedicated to discovering and advancing peptide-based therapeutics. These treatments are focused on tackling conditions related to autoimmunity, inflammation, and various infections. The company's primary drug candidate, Lupuzor, an autophagy immunomodulator, is presently in Phase III clinical trials for the management of lupus, a chronic autoimmune inflammatory disorder.
- CEO
- Timothy Paul McCarthy XIV, FCCA, MBA
- IPO
- 2017
- Employees
- 14
- HQ
- London, GB
Get TickerSpark's AI analysis on IMMPF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $28.34M
- P/E
- -10.14
- PEG
- -0.79
- P/S
- 0.00
- P/B
- 26.78
- EV/EBITDA
- -7.00
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -353.21%
- ROIC
- -308.07%
- 52W High
- $0.09
- 52W Low
- $0.08
- 50D MA
- $0.09
- 200D MA
- $0.08
- Beta
- 1.41
- Avg Volume
- 0
No earnings-call transcripts are available for IMMPF yet.
- Free Float
- 64.4%
- Shares Outstanding
- 333.40M
- Float Shares
- 214.85M
Our IMMPF coverage
Recent articles, reports, and earnings notes.
No research on IMMPF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IMMPF report →ImmuPharma appoints Kymos as third Kapiglucagon partner in build towards clinic
proactiveinvestors.co.uk · Aug 10
ImmuPharma picks Thermo Fisher to manufacture diabetes drug candidate
proactiveinvestors.co.uk · Jul 22
ImmuPharma appoints Bachem to manufacture key ingredient for diabetes drug
proactiveinvestors.co.uk · Jun 25
ImmuPharma flags Murcia research into P140 as potential brain cancer treatment
proactiveinvestors.co.uk · Jun 24
ImmuPharma focused on securing P140 licensing deal in 2026
proactiveinvestors.co.uk · May 27
ImmuPharma launches regulatory push for Kapiglucagon diabetes drug
proactiveinvestors.co.uk · May 5
ImmuPharma: P140 partnering discussions continue; overwhelming backing for investment round
proactiveinvestors.co.uk · Apr 9
ImmuPharma shares surge 20% as P140 partnering talks advance
proactiveinvestors.co.uk · Mar 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.